ENDEXX CORP (OTCMKTS:EDXC) shares down by 12.41%, Hemispherx BioPharma, Inc (NYSEMKT:HEB)

Posted by sara Frank May 31, 2013 0 Comment 1177 views


Hartford, CT 05/31/2013 (GDPInsider) – ENDEXX CORP (OTCMKTS:EDXC) opened trading session at $0.19 per share after it had closed at $0.127, down by 12.41% (-$0.018). The stock price has so far seen rise and fall ranging from $0.12 to $0.20 while in the past 52 weeks it has ranged from $0.00 – $0.20. The number of shares traded so far stands at 9.88 million as compared to the 30-day average of 608.680 thousand. It has a high beta figure of 2.89 which shows that its stock is 189% more volatile than the market, meaning that investors can expect this stock to give higher returns in case markets jump but they should also be aware that its fall will be steeper if markets go down.

Endexx has made an announcement that it is has made a definitive agreement for the acquisition of Dispense Labs, LLC which has a high class stock management structure and client server based supplying machine called Autospense.

Is EDXC a solid investment at these levels? Get valuable updates and exclusive insights here.

Hemispherx BioPharma, Inc (NYSEMKT:HEB) opened trading session at $0.23 per share after it had closed at $0.225, down by 0.66% (-$0.002). The stock price has so far seen rise and fall ranging from $0.21 to $0.24 while in the past 52 weeks it has ranged from $0.18 – $1.10. The number of shares traded so far stands at 1.42 Million as compared to the 30-day average of 369.937 thousand. Against 166.78 million outstanding shares, the company posts a dismal earnings-per-share figure of -$0.12 which means it is enduring losses and is doing badly. It has a relatively high beta figure of 1.28 which shows that its stock is 28% more volatile than the market, meaning that investors can expect this stock to give higher returns in case markets jump but they should also be aware that its fall will be steeper if markets go down.

How Should Investors Trade HEB Now? Get key and important information right here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About sara Frank

Sara Frank is our chief congressional correspondent, Sara has covered the presidential campaign, Congress and congressional campaigns. Prior to that, she covered the U.S. House. Sarahas also worked covering the House, Senate and campaign finance. Among the numerous honors she has received for his reporting, Sara is the recipient of an Emmy Award from The National Academy of Television Arts and Sciences. She was also nominated four times for a national Cable Ace Award.

View all post by sara Frank Visit author's website

Write Your Comment